ABBOTT LABORATORIES (ABT) FY2025 Q1 Balance Sheet

ABBOTT LABORATORIES (ABT) FY2025 Q1 Balance Sheet

Balance sheet as of 2025-03-31. The chart shows assets, liabilities and equity at that date.

Assets

81,448,000,000 US dollars

Current assets

23,153,000,000 US dollars

Non-current assets

58,295,000,000 US dollars

Liabilities (calculated)

32,384,000,000 US dollars

Current liabilities

13,004,000,000 US dollars

Non-current liabilities

19,380,000,000 US dollars

Equity

49,064,000,000 US dollars

Noncontrolling interest

253,000,000 US dollars. Included in consolidated equity; this amount is not added again.

Property and equipment, at cost

23,418,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Less: accumulated depreciation and amortization

negative 12,486,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Trade receivables, less allowances of $449 in 2025 and $439 in 2024

7,327,000,000 US dollars

Cash and cash equivalents

6,532,000,000 US dollars

Finished products

4,063,000,000 US dollars

Prepaid expenses and other receivables

2,343,000,000 US dollars

Materials

1,686,000,000 US dollars

Work in process

890,000,000 US dollars

Short-term investments

312,000,000 US dollars

Goodwill

23,359,000,000 US dollars

Deferred income taxes and other assets

16,836,000,000 US dollars

Net property and equipment

10,932,000,000 US dollars

Intangible assets, net of amortization

6,261,000,000 US dollars

Investments

907,000,000 US dollars

Other accrued liabilities

5,600,000,000 US dollars

Trade accounts payable

4,214,000,000 US dollars

Salaries, wages and commissions

1,167,000,000 US dollars

Dividends payable

1,032,000,000 US dollars

Current portion of long-term debt

506,000,000 US dollars

Income taxes payable

485,000,000 US dollars

Long-term debt

12,736,000,000 US dollars

Post-employment obligations, deferred income taxes and other long-term liabilities

6,644,000,000 US dollars

Earnings employed in the business

47,715,000,000 US dollars

Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2025: 1,995,858,606; 2024: 1,991,472,630

25,125,000,000 US dollars

Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued

0 US dollars

Noncontrolling Interests in Subsidiaries

253,000,000 US dollars

Common shares held in treasury, at cost — Shares: 2025: 256,021,416; 2024: 259,774,639

negative 16,612,000,000 US dollars

Accumulated other comprehensive income (loss)

negative 7,417,000,000 US dollars

Gross equity (calculated)

73,093,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.